iTeos Therapeutics’ (ITOS) “Outperform” Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note released on Thursday morning,RTT News reports. They currently have a $25.00 price target on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Friday, November 15th.

iTeos Therapeutics Stock Down 4.3 %

ITOS stock opened at $7.95 on Thursday. The stock has a market cap of $290.26 million, a PE ratio of -2.52 and a beta of 1.37. The firm’s 50-day simple moving average is $8.79 and its 200 day simple moving average is $13.05. iTeos Therapeutics has a fifty-two week low of $7.54 and a fifty-two week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.13. Equities analysts forecast that iTeos Therapeutics will post -3.46 EPS for the current fiscal year.

Insider Activity

In related news, CFO Matthew Gall purchased 5,000 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On iTeos Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its holdings in shares of iTeos Therapeutics by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock valued at $1,799,000 after purchasing an additional 5,409 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of iTeos Therapeutics by 35.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock worth $178,000 after acquiring an additional 3,172 shares in the last quarter. Panagora Asset Management Inc. raised its holdings in shares of iTeos Therapeutics by 8.9% during the second quarter. Panagora Asset Management Inc. now owns 131,553 shares of the company’s stock valued at $1,952,000 after acquiring an additional 10,787 shares during the period. Rhumbline Advisers boosted its stake in iTeos Therapeutics by 8.5% in the 2nd quarter. Rhumbline Advisers now owns 44,861 shares of the company’s stock worth $666,000 after purchasing an additional 3,513 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of iTeos Therapeutics by 17.7% in the second quarter. Victory Capital Management Inc. now owns 110,389 shares of the company’s stock worth $1,638,000 after buying an additional 16,629 shares during the period. 97.16% of the stock is currently owned by institutional investors and hedge funds.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.